This will take effect December 16, 2013
Overview and Clinical Utility:
Effective December 16, 2013, PathGroup will implement in-house testing for ImmunoCAP peanut allergen component panel. Peanut allergen component panel may be utilized to diagnose and manage peanut allergic patients. ImmunoCAP allergen components help to differentiate between “true” allergies and cross-reactivity. A better differentiation helps to give relevant advice and define the optimal treatment. Proper management helps to improve the patient’s well-being and quality of life.
Click Here to read more.